Phase IIa proof-of-concept of M 1001 in patients with combined dyslipidaemia
Latest Information Update: 26 Jul 2016
Price :
$35 *
At a glance
- Drugs M 1001 (Primary)
- Indications Dyslipidaemias
- Focus Proof of concept; Therapeutic Use
- 26 Jul 2016 New trial record